Patients in a Medicaid managed care plan who had cardiovascular comorbidities were not more likely to fill antihypertensive prescriptions than patients without these conditions.
Proactive identification of cognitive impairment and compensatory destigmatized patient/familial psychoeducation regarding “forgetfulness” in hospitalized patients with congestive heart failure may reduce readmission rates substantially.
The disparities in survival among node-positive breast cancer patients of African American and Hispanic heritage are not explained by nodal surgery utilization.
Changing patients from an inhaled corticosteroid (ICS)/long-acting β agonist (LABA) inhaler and long-acting muscarinic agonist (LAMA) inhaler to a LAMA/LABA inhaler and a separate ICS inhaler did not appear to affect patient-reported chronic obstructive pulmonary disease (COPD) symptom scores.
This study evaluated a pharmacist-managed diabetes clinic to determine its impact on diabetes-related quality measures.(For Tables and Figures, please access the PDF on last page.)
Pilot testing of guidelines for the laboratory monitoring of high-risk medications shows that monitoring is highly variable and that there is room for improvement.
Although concerns remain that expanding insurance coverage may have a “crowding-out” effect, we saw no evidence of this for Medicaid beneficiaries in Massachusetts following statewide health reform.
This decision tree model estimates the cost per response and incremental cost per additional responder for romiplostim, eltrombopag, and “watch and rescue” for immune thrombocytopenia.
We determine a specialist physician phenotype responsive to financial incentives that may be leveraged to identify physicians and markets well-suited for participation in alternative payment models.
This article presents a synthesis of opioid use disorder guidelines and a framework to link them to claims data and recognize higher-quality practice, monitor outcomes, and individualize intervention.
The authors examine real-world hepatitis C virus cure rates with direct-acting antivirals among patients coinfected with HIV.
Management of high and rising costs in oncology requires a multifaceted approach using both innovative strategies and pragmatic tools. In this article, we discuss several factors that influence the costs of oncology care.
As Medicare Advantage increasingly becomes the dominant form of Medicare coverage, Congress must improve transparency of programmatic costs and benefits to promote beneficiary choice.
Health-related quality-of-life data are often collected during routine clinical care. We present a method to create nationally representative benchmarks for clinical subspecialties.
“Frequent flyers” significantly contribute to emergency department (ED) crowding. This study developed a predictive model that can be used to identify high-risk patients and reduce ED revisits.
This paper reports findings from a qualitative analysis of US Department of Veterans Affairs hospitals on factors affecting success in implementing 2 information technology systems.
A systematic review of interactive voice response system studies showed that these interventions significantly benefit adherence to various processes of care.
The authors examine the largest 20 US commercial payers’ coverage policies and identify variation in how interventions are covered and the evidence reviewed in them.
An update on immunotherapies and the potential impact of chimeric antigen receptor (CAR)-T cells on oncology care.
We used aggregated pharmacy claims data available within the electronic health record to identify a high rate of primary nonadherence in a nonintegrated primary care network.
Analyzing factors associated with continuing care participation in patients with diabetes and with interrupted participation by patients enrolled in a diabetes pay-for-performance program.
From the Adult Diabetes and Clinical Research sections, Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts. This guideline was revised and approved May 17, 2017, and updated February 7, 2018.
This analysis of antiosteoporosis therapy shows that 75% of patients have inadequate drug coverage and that adherence is strongly associated with age and administration regimen.